AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04470427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT04470427 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT00861744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: Intramuscular injection, one dose
Study NCT00861744 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: Intramuscular injection, one dose
Study NCT00861744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar®
Description: Intramuscular injection, one dose
Study NCT04248439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L102
Description: CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
Study NCT04470427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT03196141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: StO2 and EndoPAT
Description: * StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand.
Study NCT02550795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of dexmedetomidine only
Study NCT02550795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine and dexamethasone
Description: administration of dexmedetomidine and dexamethasone
Study NCT02550795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: administration of normal saline
Study NCT02595450 — intervention group
Intervention type: DRUG
Intervention: Erlotinib
Description: Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
Study NCT00578305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied as a sterile liquid for iv administration.
Study NCT01113242 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological Assessment
Description: Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,...) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) \<16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
Study NCT02225587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
Study NCT02225587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar 13™
Description: Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
Study NCT02225587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax™ 23
Description: Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
Study NCT02225587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumovax™ 23
Description: Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
Study NCT02225587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections are to be administered into the deltoid muscle of the upper arm.
Study NCT02225587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections are to be administered into the deltoid muscle of the upper arm.
Study NCT04508816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab (CTX) or nimotuzumab (NTZ)
Description: The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
Study NCT01806129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice related to reproductive heath
Description: Patients undergo usual standard practice related to reproductive health.
Study NCT01806129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training modules, algorithm, referral development
Description: Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a sterile liquid in single-use vials for iv administration.
Study NCT01676662 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solace Bladder Control System
Description: Subjects may undergo treatment every 12 months until study completion.
Study NCT01676662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solace Bladder Control System
Description: Subjects may undergo treatment every 12 months until study completion.
Study NCT01676662 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solace Sham Treatment
Description: Sham procedure that resembles treatment with the Solace Bladder Control System
Study NCT01796522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 200 mg / day vaginally
Study NCT01796522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine (60 mg / day orally)
Study NCT04132219 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: eHealth Intervention
Description: Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study NCT04132219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Intervention
Description: Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid or folate
Study NCT00578305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid or folate
Study NCT04265183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placing preformed metal crowns using Hall technique.
Description: Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
Study NCT01534533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one gelatine capsule containing starch per day, for 12 months
Study NCT01534533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein group
Description: one gelatine capsule containing 20mg lutein per day, for 12 months
Study NCT01534533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination group
Description: one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
Study NCT02585765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 8 weeks of daily pioglitazone (30 mg/d).
Study NCT02585765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of daily placebo capsules.
Study NCT03625128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18
Description: This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
Study NCT03907215 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACT541468
Description: 50 mg; film-coated tablet for oral use
Study NCT03907215 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACT541468 placebo
Description: film-coated tablet for oral use
Study NCT01534533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal lutein control group
Description: subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
Study NCT03895866 — intervention group
Intervention type: OTHER
Intervention: The participants were assigned to different groups according to the results of HPV detection.
Description: The participants were assigned to different groups according to the results of HPV detection
Study NCT03907215 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram
Description: 20 mg; tablet tor oral use; for single- or repeated dosing
Study NCT03588338 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Perfalgan
Description: For postoperative pain
Study NCT02433652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant live attenuated trivalent dengue vaccine
Description: Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.
Study NCT02433652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03588338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perfalgan
Description: For postoperative pain
Study NCT03588338 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: For postoperative nausea and vomiting
Study NCT03588338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: For postoperative nausea and vomiting
Study NCT02172547 — intervention group
Intervention type: DRUG
Intervention: Spiriva
Study NCT00130364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus 1 % cream
Study NCT00130364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pimecrolimus vehicle cream (placebo)
Study NCT00294658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thymectomy plus prednisone
Description: The thymectomy will be performed as soon as possible after randomization.
Study NCT00294658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone alone
Description: Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
Study NCT02433652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 vaccine
Description: Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU
Study NCT02481921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group medical visits
Description: Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.
Study NCT02960451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIME care
Description: Specialist medication, cognitive behavior therapy, family-focused therapy
Study NCT02960451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Medication and psychotherapy as available form community providers
Study NCT01551173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin sodium
Description: Fluvastatin sodium Extended Release Tablets 80mg
Study NCT01551173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin sodium
Description: Fluvastatin sodium Extended Release Tablets 80mg
Study NCT06254339 — intervention group
Intervention type: PROCEDURE
Intervention: OAGB
Description: using OAGB procedure as metabolic bariatric surgery
Study NCT06254339 — intervention group
Intervention type: PROCEDURE
Intervention: DJB-SG
Description: using DJB-SG procedure as metabolic bariatric surgery
Study NCT00327093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: indication : second intention treatment
Study NCT00327093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Indication: first intention treatment
Study NCT04612400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral amino acid tracer
Description: Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
Study NCT04617951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ishige Okamurae extracts group
Description: Ishige Okamurae extracts 300 mg/day for 12 weeks
Study NCT04617951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 300 mg/day for 12 weeks
Study NCT01694238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate incision
Study NCT00706251 — intervention group
Intervention type: DEVICE
Intervention: Silicone tube
Description: Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
Study NCT03529266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Porcine Fibrin Sealant (PFS)
Description: 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
Study NCT01694238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circular incision
Study NCT01694238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesh enforced cruciate incision
Study NCT01754649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
Study NCT01754649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
Study NCT03210766 — intervention group
Intervention type: DRUG
Intervention: Nabilone
Study NCT03210766 — intervention group
Intervention type: DRUG
Intervention: THC/CBD
Study NCT03870490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 + cefepime
Description: IV infusion (3 doses)
Study NCT02098772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Study NCT02098772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Study NCT00457353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Clausii
Description: For 5 days
Study NCT00457353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral rehydration therapy
Description: For 5 days
Study NCT03529266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
Study NCT00751777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: Travelers' Diarrhea Vaccine System
Study NCT02105090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Local
Study NCT00751777 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Travelers' Diarrhea Vaccine System
Study NCT02105090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Study NCT04568109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Description: The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
Study NCT01156584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511 vector
Description: Single, stereotactic, transcranial, intratumoral injection or intravenous injection
Study NCT01156584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: 4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
Study NCT00657605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin
Description: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
Study NCT02273947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified
Study NCT02607072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)/aspirin 200 mg daily
Study NCT02607072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)/aspirin 100 mg daily
Study NCT02607072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03884764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected